US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

- FDA Fast Track designation facilitates the development of potential new therapies that treat serious conditions and fulfill an unmet medical need   - This Fast Track designation for empagliflozin emphasizes the urgent need for potential treatments that may improve outcomes following an acute